N-(bis-methylsulfanyl-methylidene)-3-fluorobenzenesulfonamide | 1094408-95-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(bis-methylsulfanyl-methylidene)-3-fluorobenzenesulfonamide
• 英文别名: N-[bis(methylthio)methylene]-3-fluorobenzenesulfonamide；N-[bis(methylsulfanyl)methylidene]-3-fluorobenzenesulfonamide
• CAS: 1094408-95-3
• 化学式: C₉H₁₀FNO₂S₃
• 分子量: 279.38
• InChiKey: XVWVBKMUDPDGCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(bis-methylsulfanyl-methylidene)-3-fluorobenzenesulfonamide 、 3,3'-二羟基联苯胺 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.5h， 以75%的产率得到3-fluoro-N-[6-[2-[(3-fluorophenyl)sulfonylamino]-1,3-benzoxazol-6-yl]-1,3-benzoxazol-2-yl]benzenesulfonamide
  参考文献：
  名称：

  小分子信号转导子和转录激活因子3抑制剂的发现，合成和评估。

  摘要：

  转录3（STAT3）癌基因的信号转导和激活剂是一种有前途的分子靶标，其抑制剂作为抗癌药物具有巨大的潜力。为了鉴定新型和STAT3选择性抑制剂，基于Specs和Maybridge数据库进行了虚拟筛选，并探索了对STAT3的抑制常数K（i）为494.32 nM的6,6'-联苯并恶唑型小分子化合物3a。 。此外，使用人乳腺癌细胞系MDA-MB-468和MCF-7分别具有或不具有STAT3的组成性表达，通过基于细胞的分析合成并评估了最初衍生自3a的一系列新衍生物。在该系列中，3a，3c，3d和4e表现出更好的抑制活性和良好的选择性。其中，3a和3c显着抑制STAT3蛋白水平，并且还显示出对STAT3的结合亲和力，该流动性分析用石英晶体微天平（FIA-QCM）分析系统检测到。结果为有效的STAT3抑制剂的未来设计和开发提供了新的线索。

  DOI：

  10.1248/cpb.c12-00745
• 作为产物：
  描述：

  二硫化碳 、 间氟苯磺酰胺 、 碘甲烷 在 potassium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以48%的产率得到N-(bis-methylsulfanyl-methylidene)-3-fluorobenzenesulfonamide
  参考文献：
  名称：

  N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT₆R) Antagonists with Unique Structural Features

  摘要：

  The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-containing scaffolds dominating the field. High-throughput screening identified the N'-(sulfonyl)pyrazoline-1-carboxamidine scaffold as a promising neutral core for starting hit-to-lead. Medicinal chemistry, molecular modeling, small molecule NMR and X-ray crystallography were subsequently applied to optimize the leads into antagonists (compounds 1-49) displaying high 5-HT6R affinity with optimal off-target selectivity. Unique structural features include a pseudoaromatic system and an internal hydrogen bond freezing the bioactive conformation. While physicochemical properties and CNS availability were generally favorable, significant efforts had to be made to improve metabolic stability. The optimized structure 42 is an extremely selective, hERG-free, high-affinity 5-HT6R antagonist showing good human in vitro metabolic stability. Rat pharrnacokinetic data were sufficiently good to enable further in vivo profiling.

  DOI：

  10.1021/jm200466r

文献信息

• <i>N</i>′-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT₆R) Antagonists with Unique Structural Features
  作者：Arnold van Loevezijn、Jennifer Venhorst、Wouter I. Iwema Bakker、Cor G. de Korte、Wouter de Looff、Stefan Verhoog、Jan-Willem van Wees、Martijn van Hoeve、Rob P. van de Woestijne、Martina A. W. van der Neut、Alice J. M. Borst、Maria J. P. van Dongen、Natasja M. W. J. de Bruin、Hiskias G. Keizer、Chris G. Kruse

  DOI：10.1021/jm200466r

  日期：2011.10.27

  The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-containing scaffolds dominating the field. High-throughput screening identified the N'-(sulfonyl)pyrazoline-1-carboxamidine scaffold as a promising neutral core for starting hit-to-lead. Medicinal chemistry, molecular modeling, small molecule NMR and X-ray crystallography were subsequently applied to optimize the leads into antagonists (compounds 1-49) displaying high 5-HT6R affinity with optimal off-target selectivity. Unique structural features include a pseudoaromatic system and an internal hydrogen bond freezing the bioactive conformation. While physicochemical properties and CNS availability were generally favorable, significant efforts had to be made to improve metabolic stability. The optimized structure 42 is an extremely selective, hERG-free, high-affinity 5-HT6R antagonist showing good human in vitro metabolic stability. Rat pharrnacokinetic data were sufficiently good to enable further in vivo profiling.
• Discovery, Synthesis, and Evaluation of Small-Molecule Signal Transducer and Activator of Transcription 3 Inhibitors
  作者：Zhi-Bing Shi、Dan Zhao、Yan-Yan Huang、Yun Du、Xiang-Rong Cao、Zhu-Nan Gong、Rui Zhao、Jian-Xin Li

  DOI：10.1248/cpb.c12-00745

  日期：——

  The signal transducer and activator of transcription 3 (STAT3) oncogene is a promising molecular target and its inhibitors have great potential as anticancer drugs. To identify novel and STAT3-selective inhibitors, a virtual screening based on Specs and Maybridge databases was conducted and a 6,6'-bibenzoxazole type small molecule, compound 3a with a inhibition constant K(i) value of 494.32 nM to STAT3

  转录3（STAT3）癌基因的信号转导和激活剂是一种有前途的分子靶标，其抑制剂作为抗癌药物具有巨大的潜力。为了鉴定新型和STAT3选择性抑制剂，基于Specs和Maybridge数据库进行了虚拟筛选，并探索了对STAT3的抑制常数K（i）为494.32 nM的6,6'-联苯并恶唑型小分子化合物3a。 。此外，使用人乳腺癌细胞系MDA-MB-468和MCF-7分别具有或不具有STAT3的组成性表达，通过基于细胞的分析合成并评估了最初衍生自3a的一系列新衍生物。在该系列中，3a，3c，3d和4e表现出更好的抑制活性和良好的选择性。其中，3a和3c显着抑制STAT3蛋白水平，并且还显示出对STAT3的结合亲和力，该流动性分析用石英晶体微天平（FIA-QCM）分析系统检测到。结果为有效的STAT3抑制剂的未来设计和开发提供了新的线索。